Working... Menu

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02191332
Recruitment Status : Completed
First Posted : July 16, 2014
Last Update Posted : July 16, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

Condition or disease Intervention/treatment
HIV Infections Drug: Viramune

Layout table for study information
Study Type : Observational
Actual Enrollment : 147 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen
Study Start Date : December 1999
Actual Primary Completion Date : November 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
Drug Information available for: Nevirapine

Group/Cohort Intervention/treatment
Viramune Drug: Viramune

Primary Outcome Measures :
  1. Change in viral load (HIV-RNA) [ Time Frame: Baseline, after 26 and 52 weeks ]
  2. Change in CD4 cell count [ Time Frame: Baseline, after 26 and 52 weeks ]
  3. Change in lipid status (lipodystrophy, triglycerides, cholesterol) [ Time Frame: Baseline, after 26 and 52 weeks ]
    verbal rating scale

  4. Change in glucose tolerance [ Time Frame: Baseline, after 26 and 52 weeks ]
    verbal rating scale

Secondary Outcome Measures :
  1. Assessment of subjective well-being [ Time Frame: up to 52 weeks ]
    verbal rating scale

  2. Assessment of tolerability by physician and patient [ Time Frame: after 26 and 52 weeks ]
    verbal rating scale

  3. Number of patients with adverse events [ Time Frame: up to 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV treatment centres and HIV out-patient facilities

Inclusion Criteria:

  • Adult male or female patients with HIV type 1 infection

Exclusion Criteria:

  • Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
  • No persons under 18
  • Pregnancy and breast-feeding
  • Use of oral contraceptives
  • Use of drugs affecting CYP450 3A metabolism

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02191332     History of Changes
Other Study ID Numbers: 1100.1305
First Posted: July 16, 2014    Key Record Dates
Last Update Posted: July 16, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Acquired Immunodeficiency Syndrome
Immunologic Deficiency Syndromes
Communicable Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immune System Diseases
Slow Virus Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers